1. Sharma P, Sandhu SV, Bhandari R, Verma I, Bhullar RK, Khangura RK. Estimation of cortisol levels in patients with premalignant disorders and oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2018;22:27-34.

https://doi.org/10.4103/jomfp.JOMFP_181_16

PMid:29731553 PMCid:PMC5917537

2. Bernabé DG, Tamae AC, Miyahara GI, Sundefeld ML, Oliveira SP, Biasoli ÉR. Increased plasma and salivary cortisol levels in patients with oral cancer and their association with clinical stage. J Clin Pathol. 2012;65:934-9.

https://doi.org/10.1136/jclinpath-2012-200695

PMid:22734006 

3. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423-37.

https://doi.org/10.1038/nm.3394

PMid:24202395 PMCid:PMC3954707

4. Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, González-Moles MA, Kerr AR, et al. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 2021;27:1862-80.

https://doi.org/10.1111/odi.13704

PMid:33128420 

5. Liu W, Wu L, Zhang Y, Shi L, Yang X. Bibliometric analysis of research trends and characteristics of oral potentially malignant disorders. Clin Oral Investig. 2020;24:447-54.

https://doi.org/10.1007/s00784-019-02959-0

PMid:31111281 

6. Mello FW, Miguel AFP, Dutra KL. Prevalence of oral potentially malignant disorders: a systematic review and meta- analysis. J Oral Pathol Med. 2018;47:633-40.

https://doi.org/10.1111/jop.12726

PMid:29738071 

7. Iocca O, Sollecito TP, Alawi F, Weinstein GS, Newman JG, De Virgilio A, et al. Potentially malignant disorders of the oral cavity and oral dysplasia: A systematic review and meta-analysis of malignant transformation rate by subtype. Head Neck. 2020;42:539-55.

https://doi.org/10.1002/hed.26006

PMid:31803979 

8. Warnakulasuriya S, Ariyawardana A. Malignant transformation of oral leukoplakia: a systematic review of observational studies. J Oral Pathol Med. 2016;45:155-66.

https://doi.org/10.1111/jop.12339

PMid:26189354 

9. Kalavrezos N, Scully C. Mouth cancer for clinicians part 6: Potentially malignant disorders. Dent Update. 2015;42:866-88.

https://doi.org/10.12968/denu.2015.42.9.866

PMid:26749794 

10. González-Moles MÁ, Ruiz-Ávila I, González-Ruiz L, Ayén Á, Gil-Montoya JA, Ramos-García P. Malignant transformation risk of oral lichen planus: A systematic review and comprehensive meta- analysis. Oral Oncol. 2019;96:121-30.

https://doi.org/10.1016/j.oraloncology.2019.07.012

PMid:31422203 

11. Hankinson PM, Mohammed-Ali RI, Smith AT, Khurram SA. Malignant transformation in a cohort of patients with oral epithelial dysplasia. Br J Oral Maxillofac Surg. 2021;59:1099-101.

https://doi.org/10.1016/j.bjoms.2021.02.019

PMid:34303542 

12. Holmes TH, Rahe RH. The Social Readjustment Rating Scale. J Psychosom Res. 1967;11:213-8.

https://doi.org/10.1016/0022-3999(67)90010-4

PMid:6059863 

13. Bernabé DG, Tamae  AC, Biasoli ER, Oliveira SH. Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells. Brain, behavior, and immunity. 2011;25:574-83.

https://doi.org/10.1016/j.bbi.2010.12.012

PMid:21187140 

14. Saul AN, Oberyszyn TM, Daugherty C, Kusewitt D, Jones S, Jewell S, et al. Chronic stress and susceptibility to skin cancer. J Natl Cancer Inst. 2005;97:1760-7.

https://doi.org/10.1093/jnci/dji401

PMid:16333031 PMCid:PMC3422720

15. Lichter I, Sirett NE. Serial measurement of plasma cortisol in lung cancer. Thorax. 1975;30:91-4.

https://doi.org/10.1136/thx.30.1.91

PMid:1124533 PMCid:PMC470250

16. Paleri V, Wight RG, Silver CE, Haigentz M Jr, Takes RP, Bradley PJ, et al. Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol. 2010;46:712-9.

https://doi.org/10.1016/j.oraloncology.2010.07.008

PMid:20850371 

17. Heikkilä K, Ebrahim S, Lawlor DA. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer. 2008;44:937-45.

https://doi.org/10.1016/j.ejca.2008.02.047

PMid:18387296 

18. Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer. 2006;119:1268-75.

https://doi.org/10.1002/ijc.21967

PMid:16642480 

19. Allende S, Medina JL, Spiegel D, Zeitzer JM. Evening salivary cortisol as a single stress marker in women with metastatic breast cancer. Psychoneuroendocrinology. 2020;115:104648.

https://doi.org/10.1016/j.psyneuen.2020.104648

PMid:32171899 

20. Weinrib AZ, Sephton SE, Degeest K, Penedo F, Bender D, Zimmerman B, et al. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer. 2010;116:4410-9.

https://doi.org/10.1002/cncr.25299

PMid:20564155 PMCid:PMC3118555

21. Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, et al. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain Behav Immun. 2013;30:126-34.

https://doi.org/10.1016/j.bbi.2012.07.022

PMid:22884960 PMCid:PMC3697797

22. Cruz MSP, Reis TG, Oliveira AC, Macedo MM, De Bessa J, Oliveira MC. Nighttime salivary cortisol as a biomarker of stress and an indicator of worsening quality of life in patients with head and neck cancer: a cross-sectional study. Health Sci Rep. 2022;5:783.

https://doi.org/10.1002/hsr2.783

PMid:35957977 PMCid:PMC9364433